CN116997339A - 作为治疗剂的cGAS活性抑制剂 - Google Patents
作为治疗剂的cGAS活性抑制剂 Download PDFInfo
- Publication number
- CN116997339A CN116997339A CN202280019484.7A CN202280019484A CN116997339A CN 116997339 A CN116997339 A CN 116997339A CN 202280019484 A CN202280019484 A CN 202280019484A CN 116997339 A CN116997339 A CN 116997339A
- Authority
- CN
- China
- Prior art keywords
- pyrrolidine
- methylbenzofuran
- pyrimidin
- carboxylic acid
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163148201P | 2021-02-11 | 2021-02-11 | |
| US63/148,201 | 2021-02-11 | ||
| PCT/US2022/016073 WO2022174012A1 (en) | 2021-02-11 | 2022-02-11 | INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116997339A true CN116997339A (zh) | 2023-11-03 |
Family
ID=82837325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280019484.7A Pending CN116997339A (zh) | 2021-02-11 | 2022-02-11 | 作为治疗剂的cGAS活性抑制剂 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240174684A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4291188A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024506904A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230144550A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116997339A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022218787A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3206520A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022174012A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023020381A2 (pt) * | 2021-05-12 | 2023-11-21 | Boehringer Ingelheim Int | Derivados de piridina com substituintes cíclicos ligados por c como inibidores de cgas |
| CN117337292A (zh) | 2021-05-12 | 2024-01-02 | 勃林格殷格翰国际有限公司 | 作为cGAS抑制剂的具有N-连接环状取代基的吡啶衍生物 |
| WO2024035622A1 (en) * | 2022-08-10 | 2024-02-15 | Bellbrook Labs, Llc | INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS |
| CA3267076A1 (en) * | 2022-11-09 | 2024-05-16 | Boehringer Ingelheim International Gmbh | CYCLIC PYRIDINE DERIVATIVES USED AS CGAS INHIBITORS |
| CN121248633A (zh) * | 2022-11-09 | 2026-01-02 | 勃林格殷格翰国际有限公司 | 作为cGAS抑制剂的环状苯并咪唑衍生物 |
| WO2025233174A1 (en) | 2024-05-08 | 2025-11-13 | Boehringer Ingelheim International Gmbh | Benzimidazole derivatives as cgas inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2441958T3 (es) * | 2006-07-11 | 2014-02-07 | Janssen Pharmaceutica Nv | Moduladores de benzofuro- y benzotienopirimidina del receptor de histamina H4 |
| WO2008074445A1 (en) * | 2006-12-18 | 2008-06-26 | Ucb Pharma, S.A. | Novel tricyclic and heterotricyclic derivatives, processes for preparing them, pharmaceutical compositions thereof |
| WO2013115167A1 (ja) * | 2012-01-31 | 2013-08-08 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | アムバチニブ誘導体 |
| US20200016136A1 (en) * | 2017-01-03 | 2020-01-16 | Viiv Healthcare Uk (No. 5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| WO2020142729A1 (en) * | 2019-01-04 | 2020-07-09 | BellBrook Labs | Inhibitors of cgas activity as therapeutic agents |
-
2022
- 2022-02-11 CN CN202280019484.7A patent/CN116997339A/zh active Pending
- 2022-02-11 AU AU2022218787A patent/AU2022218787A1/en not_active Abandoned
- 2022-02-11 WO PCT/US2022/016073 patent/WO2022174012A1/en not_active Ceased
- 2022-02-11 CA CA3206520A patent/CA3206520A1/en active Pending
- 2022-02-11 EP EP22753392.4A patent/EP4291188A4/en active Pending
- 2022-02-11 KR KR1020237028625A patent/KR20230144550A/ko active Pending
- 2022-02-11 US US18/275,190 patent/US20240174684A1/en not_active Abandoned
- 2022-02-11 JP JP2023548654A patent/JP2024506904A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240174684A1 (en) | 2024-05-30 |
| KR20230144550A (ko) | 2023-10-16 |
| CA3206520A1 (en) | 2022-08-18 |
| JP2024506904A (ja) | 2024-02-15 |
| AU2022218787A1 (en) | 2023-08-17 |
| WO2022174012A1 (en) | 2022-08-18 |
| EP4291188A1 (en) | 2023-12-20 |
| EP4291188A4 (en) | 2025-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019294835B2 (en) | Ligands to cereblon (CRBN) | |
| JP6959248B2 (ja) | 癌治療用の4,6−ジヒドロピロロ[3,4−c]ピラゾール−5(1H)−カルボニトリル誘導体 | |
| ES2660914T3 (es) | Derivados de 6-(5-hidroxi-1H-pirazol-1-il)nicotinamida y su uso como inhibidores de PHD | |
| CN107614499B (zh) | 吡啶并[3,4-d]嘧啶衍生物及其药学上可允许的盐 | |
| AU2005212409C1 (en) | Pyrazolopyrimidine-derivatives as cyclin dependent kinase inhibitors | |
| KR20230144550A (ko) | 치료제로서의 cGAS 활성의 저해제 | |
| JP2022547014A (ja) | ヘテロ環式rip1キナーゼ阻害剤 | |
| RS65319B1 (sr) | 8-cijano-5-piperidino-hinolini kao tlr7/8 antagonisti i njihova upotreba u lečenju imunoloških poremećaja | |
| CN107428765B (zh) | 用作irak抑制剂的哒嗪酮类大环化合物及其用途 | |
| BR112021002479A2 (pt) | composto, composição farmacêutica, método para inibir a atividade de itk ou jak3 em uma população de células, método para tratar um distúrbio mediado por itk ou jak3 em um indivíduo necessitando do mesmo e uso de um composto | |
| WO2018090939A1 (zh) | 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物 | |
| AU2022202886B2 (en) | Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof | |
| JP2022169796A (ja) | 非アポトーシス性の制御された細胞死の阻害剤としてのスピロキノキサリン誘導体 | |
| RU2722383C2 (ru) | Производные хромена в качестве ингибиторов фосфоинозитид-3-киназ | |
| US12427146B2 (en) | C-terminal SRC kinase inhibitors | |
| KR20210112316A (ko) | 치료제로서의 cgas 활성 억제제 | |
| CN107074856A (zh) | CaMKII抑制剂及其用途 | |
| CN108463222A (zh) | 用于治疗疾病的杂环化合物 | |
| JP7712941B2 (ja) | トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物 | |
| CN119698277A (zh) | 作为治疗剂的cGAS活性抑制剂 | |
| CA2821777A1 (en) | Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway | |
| CN115894376B (zh) | 一种芳香族酰胺类化合物、药物组合物及其用途 | |
| WO2025255442A1 (en) | Trim21-targeted compounds and uses thereof | |
| ES2371358T3 (es) | Compuesto de benzoimidazol capaz de inhibir prostaglandina d sintetasa. | |
| HK40043591B (en) | Heteroaryl compounds as type ii irak inhibitors and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |